The Association of Pharmaceutical Companies «Innovative Pharma» (InPharma) brings together major pharmaceutical companies that actively invest in research and development and are counted among the top 20 global pharmaceutical producers. Members of the Association have research facilities all over the world and also work with Russian R&D centers to conduct clinical trials, cooperating with more than 250 R&D facilities across Russia.

Members of the Association carry out research and development in the key fields of medicine, such as cardiology, endocrinology, psychiatry, neurology, oncology, urology, gastroenterology and diabetology.

With a view towards developing partnership for innovative pharmaceutical R&D, members of the Association enter into partnership agreements with the Russian development institutions – the Skolkovo Innovation Centre and the Russian Venture Capital Company, as well as develop projects to modernize the biomedicine and biopharmaceutical sectors in Russia, and invest in the construction of manufacturing facilities and research laboratories.

Promote the development of innovation in the pharmaceutical sector in Russia in order to improve the nation's health.

Promote the development and maintenance of favorable conditions and economic sustainability of the healthcare system in Russia.

Pursue extensive dialogue on information policy and openness with regulators, public authorities, the professional healthcare community and patients.

Promote interaction with Government authorities and healthcare professional communities with the goal to formulate health policies and to improve the quality and accessibility of medicines for the population of Russia.


Create conditions for the effective interaction between members of the association that provide for the exchange of ideas and opinions on the development of innovative pharmaceutical companies and the healthcare system in general.

Protect and maintain the intellectual property rights of innovative drugs.

Provide interaction between representatives of innovative pharmaceutical companies and healthcare professionals in accordance with the laws of the Russian Federation.

Represent and protect the interests of members of the Association within Government and healthcare authorities.

Unite innovative companies in the vendor community and formulate consolidated positions on the development and regulation of the industry.

Participate in the reform of existing approaches to pricing and reimbursement of medicines.

Develop and maintain cooperation with international associations which unite innovative pharmaceutical companies